FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211321963> ?p ?o ?g. }

• W3211321963 endingPage "8580" @default.
• W3211321963 startingPage "8570" @default.
• W3211321963 abstract "Limited real-world data exist on treatment patterns and outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC).A retrospective cohort study was conducted, using the Veterans Health Administration claims database (April 2013-March 2018). Among 369,734 prostate cancer patients, we selected all men who developed metastases within 90 days before or after medical/surgical castration and who received androgen deprivation therapy (ADT). Patients were categorized into four cohorts: ADT-only (± <90-day nonsteroidal anti-androgen [NSAA] use), ADT + NSAA, ADT + docetaxel, and ADT + abiraterone. Main outcomes were treatment patterns, time-to-progression to metastatic castration-resistant disease, and overall survival. Multivariable analysis and sensitivity analysis were conducted.Of 1395 patients, 874 (63%) received ADT-only, 338 (24%) received ADT + NSAA, 108 (8%) received ADT + docetaxel, and 75 (5%) received ADT + abiraterone. Proportions on ADT-only and ADT + NSAA declined (from 66% to 60% and from 31% to 17%, respectively) over the study period, while proportions prescribed ADT + docetaxel or abiraterone increased from 3% to 9% and from 1% to 15%, respectively. Patients treated with ADT + NSAA had similar risks of castration-resistant disease (hazard ratio [HR] 1.05; 95% confidence interval [CI]: 0.87, 1.26) and overall mortality (HR 1.22; 95% CI: 0.97, 1.54) as ADT-only.Most patients with mCSPC initiating ADT received ADT-only or ADT + NSAA, despite the emergence of docetaxel and novel hormonal therapies. Even in the most recent period (2017 to early 2018), only 24% of men received intensified therapy with agents known to prolong survival versus ADT-only. These data in real-world clinical practice suggest substantial room for improved outcomes in patients with mCSPC." @default.
• W3211321963 created "2021-11-08" @default.
• W3211321963 creator A5007663088 @default.
• W3211321963 creator A5008182909 @default.
• W3211321963 creator A5018065813 @default.
• W3211321963 creator A5020043337 @default.
• W3211321963 creator A5036003731 @default.
• W3211321963 creator A5042175259 @default.
• W3211321963 creator A5048226529 @default.
• W3211321963 creator A5049033122 @default.
• W3211321963 creator A5063316982 @default.
• W3211321963 date "2021-11-02" @default.
• W3211321963 modified "2023-10-14" @default.
• W3211321963 title "Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration" @default.
• W3211321963 cites W1504707696 @default.
• W3211321963 cites W2149199519 @default.
• W3211321963 cites W2150865892 @default.
• W3211321963 cites W2206238447 @default.
• W3211321963 cites W2214621962 @default.
• W3211321963 cites W2464502417 @default.
• W3211321963 cites W2539277011 @default.
• W3211321963 cites W2620746860 @default.
• W3211321963 cites W2620798309 @default.
• W3211321963 cites W2787816609 @default.
• W3211321963 cites W2938589827 @default.
• W3211321963 cites W2946827226 @default.
• W3211321963 cites W2947014957 @default.
• W3211321963 cites W2947893479 @default.
• W3211321963 cites W2963794755 @default.
• W3211321963 cites W2975895768 @default.
• W3211321963 cites W2999047517 @default.
• W3211321963 cites W3028698582 @default.
• W3211321963 cites W3028956388 @default.
• W3211321963 cites W3031481621 @default.
• W3211321963 cites W3088242837 @default.
• W3211321963 cites W3088910739 @default.
• W3211321963 cites W3119005666 @default.
• W3211321963 cites W3124546863 @default.
• W3211321963 cites W3211321963 @default.
• W3211321963 cites W4298017640 @default.
• W3211321963 doi "https://doi.org/10.1002/cam4.4372" @default.
• W3211321963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34725947" @default.
• W3211321963 hasPublicationYear "2021" @default.
• W3211321963 type Work @default.
• W3211321963 sameAs 3211321963 @default.
• W3211321963 citedByCount "17" @default.
• W3211321963 countsByYear W32113219632021 @default.
• W3211321963 countsByYear W32113219632022 @default.
• W3211321963 countsByYear W32113219632023 @default.
• W3211321963 crossrefType "journal-article" @default.
• W3211321963 hasAuthorship W3211321963A5007663088 @default.
• W3211321963 hasAuthorship W3211321963A5008182909 @default.
• W3211321963 hasAuthorship W3211321963A5018065813 @default.
• W3211321963 hasAuthorship W3211321963A5020043337 @default.
• W3211321963 hasAuthorship W3211321963A5036003731 @default.
• W3211321963 hasAuthorship W3211321963A5042175259 @default.
• W3211321963 hasAuthorship W3211321963A5048226529 @default.
• W3211321963 hasAuthorship W3211321963A5049033122 @default.
• W3211321963 hasAuthorship W3211321963A5063316982 @default.
• W3211321963 hasBestOaLocation W32113219633 @default.
• W3211321963 hasConcept C121608353 @default.
• W3211321963 hasConcept C126322002 @default.
• W3211321963 hasConcept C143998085 @default.
• W3211321963 hasConcept C207103383 @default.
• W3211321963 hasConcept C2775832370 @default.
• W3211321963 hasConcept C2777899217 @default.
• W3211321963 hasConcept C2780192828 @default.
• W3211321963 hasConcept C2781190966 @default.
• W3211321963 hasConcept C44249647 @default.
• W3211321963 hasConcept C71924100 @default.
• W3211321963 hasConcept C72563966 @default.
• W3211321963 hasConceptScore W3211321963C121608353 @default.
• W3211321963 hasConceptScore W3211321963C126322002 @default.
• W3211321963 hasConceptScore W3211321963C143998085 @default.
• W3211321963 hasConceptScore W3211321963C207103383 @default.
• W3211321963 hasConceptScore W3211321963C2775832370 @default.
• W3211321963 hasConceptScore W3211321963C2777899217 @default.
• W3211321963 hasConceptScore W3211321963C2780192828 @default.
• W3211321963 hasConceptScore W3211321963C2781190966 @default.
• W3211321963 hasConceptScore W3211321963C44249647 @default.
• W3211321963 hasConceptScore W3211321963C71924100 @default.
• W3211321963 hasConceptScore W3211321963C72563966 @default.
• W3211321963 hasFunder F4320307765 @default.
• W3211321963 hasFunder F4320307769 @default.
• W3211321963 hasIssue "23" @default.
• W3211321963 hasLocation W32113219631 @default.
• W3211321963 hasLocation W32113219632 @default.
• W3211321963 hasLocation W32113219633 @default.
• W3211321963 hasLocation W32113219634 @default.
• W3211321963 hasOpenAccess W3211321963 @default.
• W3211321963 hasPrimaryLocation W32113219631 @default.
• W3211321963 hasRelatedWork W2158933186 @default.
• W3211321963 hasRelatedWork W2568045406 @default.
• W3211321963 hasRelatedWork W2588988563 @default.
• W3211321963 hasRelatedWork W2590124563 @default.
• W3211321963 hasRelatedWork W2591232777 @default.
• W3211321963 hasRelatedWork W2770702948 @default.
• W3211321963 hasRelatedWork W2804874937 @default.

• next